Power and pharmaceuticals express different sides of India’s economic expansion. Comparing them requires more than choosing the sector with the stronger recent stock chart.
The power case
The Central Electricity Authority projects peak demand of 277.2 GW and energy requirements of 1,907.8 billion units in FY2026–27, rising to 366.4 GW and 2,473.8 billion units by FY2031–32. The IEA expects Indian electricity demand to rebound about 7% in 2026. Generation, transmission, storage and distribution therefore require sustained investment.
Risks include regulated returns, receivables from distribution companies, project execution, fuel availability and crowded valuations. Order books matter only when converted into profitable cash flow.
The pharma case
Pharmexcil reports pharmaceutical exports of $31.11 billion in FY2026, roughly double FY2014’s $15.44 billion. India supplies about 20% of global generic-medicine demand by volume, while complex generics, biosimilars and APIs offer higher-value opportunities.
Risks include US pricing pressure, product concentration, regulatory observations, litigation and R&D failure. Defensive demand does not make every manufacturer defensive.
Portfolio implication
Power is primarily a domestic capital-cycle exposure; pharma combines domestic healthcare demand with foreign-currency export earnings. Their economic drivers can diversify one another.
The bottom line: Investors should compare balance-sheet strength, return on capital, cash conversion and valuation company by company. Themes identify opportunity; execution determines returns.
Data references: CEA National Electricity Plan and 20th Electric Power Survey; IEA Electricity Mid-Year Update 2026; Pharmexcil FY2026 export data; Economic Survey 2025–26.